Silo Pharma issues letter to shareholders on progress of lead assets

Silo Pharma (SILO) issued a letter to shareholders highlighting the Company’s progress and potential for its lead assets SPC-15 and SP-26 as treatments for mental health and chronic pain management, respectively. The company wrote, “Silo Pharma is gaining momentum along its path to first-in-human trials for lead candidate SPC-15, an intranasal prophylactic targeting PTSD and stress induced anxiety disorder. We are currently conducting a GLP-compliant pharmacokinetic and pharmacodynamic study and believe this will be the final data required before we submit an investigational new drug application to the FDA. I’m proud to report that we are getting closer to in-human trials. In addition to SPC-15, we are advancing development of our SP-26 ketamine implant and continuing studies of our other investigational drugs.”